SCHEMBL5683198

SCHEMBL5683198

c1ccc(-n2ncc3cccnc32)nc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.67
CYP17A1 P05093 2/20 0.47
IRAK4 Q9NWZ3 5/20 0.46
ALDH1A1 P00352 1/20 0.42
GAA P10253 1/20 0.42
CYP1A2 P05177 1/20 0.42
RAB9A P51151 2/20 0.41
DPP4 P27487 1/20 0.41
FFAR4 Q5NUL3 3/20 0.40
GSK3B P49841 1/20 0.40
KDM4D Q6B0I6 1/20 0.40
PDE10A Q9Y233 1/20 0.39
NPC1 O15118 1/20 0.39
TP53 P04637 1/20 0.39
HPGD P15428 1/20 0.39
SLC2A1 P11166 1/20 0.38
SLC2A2 P11168 1/20 0.38
SLC2A3 P11169 1/20 0.38
AURKA O14965 1/20 0.38
FLT3 P36888 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29714856 1.00 KDM4E (0.67) KDM4ECYP17A1IRAK4ALDH1A1GAA
SCHEMBL4201391 0.80 KDM4E (1.00) KDM4ECYP17A1ALDH1A1GAACYP1A2
SCHEMBL31020506 0.80 IRAK4 (0.57) KDM4ECYP17A1IRAK4ALDH1A1GAA
SCHEMBL12075537 0.80 IRAK4 (0.57) KDM4ECYP17A1IRAK4ALDH1A1GAA
SCHEMBL18367194 0.77 IRAK4 (0.42) KDM4ECYP17A1IRAK4CYP1A2RAB9A
SCHEMBL29387304 0.77 IRAK4 (0.42) KDM4ECYP17A1IRAK4CYP1A2RAB9A
SCHEMBL30405070 0.77 KDM4E (0.55) KDM4ECYP17A1KDM4D
SCHEMBL19100208 0.77 KDM4E (0.55) KDM4ECYP17A1ALDH1A1CYP1A2KDM4D
SCHEMBL31661111 0.77 IRAK4 (0.51) IRAK4
SCHEMBL21090450 0.76 KDM4E (0.50) KDM4EIRAK4KDM4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060252045-A1 Methods and materials for identifying agents which modulate bone remodeling and agents identified thereby WYETH 2006-11-09 US disclosed
EP-1636388-A2 METHODS AND MATERIALS FOR IDENTIFYING AGENTS WHICH MODULATE BONE REMODELING AND AGENTS IDENTIFIED THEREBY Wyeth (US) 2006-03-22 EP disclosed
WO-2005028678-A2 METHODS AND MATERIALS FOR IDENTIFYING AGENTS WHICH MODULATE BONE REMODELING AND AGENTS IDENTIFIED THEREBY WYETH (US) 2005-03-31 WO disclosed
EP-0230622-A1 6H-Isoxazol[5,4-d]pyrazolo[3,4-b]pyridines, a process and intermediates for their preparation and their use as medicaments HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) 1987-08-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060252045-A1 Methods and materials for identifying agents which modulate bone remodeling and agents identified thereby BMP4, BMP2, BMP6 KDM4E 2004/4885CYP17A1 4431/4885IRAK4 2122/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.